Dáil Éireann Debate, Tuesday - 18 September 2018
391. Deputy Kevin O'Keeffe asked the Minister for Health the progress made in the availability of a specific drug (details supplied); and if the application submitted to supply this drug here will be expedited. [37035/18]
Amharc ar fhreagraThe Health Service Executive has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. The 2013 Act does not give the Minister for Health any powers in this regard.
The Act specifies the criteria to be applied in the making of reimbursement decisions which include the clinical and cost effectiveness of the product, the opportunity cost and the impact on resources that are available to the HSE.
The HSE received a new application for the reimbursement of Ataluren (Translarna) from PTC Therapeutics in August 2018.
The application is being assessed in accordance with the criteria set out in the Health (Pricing and Supply of Medical Goods) Act 2013, and the statutory process is ongoing.
